RxSight narrows Q4 loss to $0.03, posts $32.6M revenue beat
RxSight reported a fourth-quarter adjusted loss of $0.03 per share, outperforming estimates of a $0.23 loss by 87%, and revenue of $32.61 million topped consensus by 0.02%, though down from $40.21 million year-over-year. It has beaten EPS and revenue forecasts in each of the past four quarters.
1. Q4 Earnings Beat
RxSight delivered an adjusted loss of $0.03 per share in Q4, exceeding the consensus forecasted loss of $0.23 by 87%. This marks the fourth consecutive quarter in which the company has surpassed EPS estimates.
2. Revenue and Year-Over-Year Change
The company generated $32.61 million in revenue for the quarter, narrowly beating projections by 0.02% but down from $40.21 million a year earlier, indicating continued pressure on sales growth.
3. Outlook and Market Reaction
Analysts forecast a $0.09 per-share loss on $31.78 million in Q1 revenue and a full-year loss of $0.30 on $135.46 million in sales. RxSight shares have fallen 14.2% year-to-date, lagging the broader market.